Different women. Diverse lifestyles. One targeted treatment.

Clinically proven non-invasive treatment for uterine fibroids and adenomyosis* and ongoing research for non-invasive treatment of breast cancer


Innovative ExAblate® One expands treatment choices for women suffering from uterine fibroids and adenomyosis* and is the first and only commercially approved focused ultrasound therapeutic application for uterine fibroids. 

The ExAblate One system treats symptomatic uterine fibroids in an outpatient procedure and provides ablation of fibroids and sustained system relief. The system enables precise treatment validation; outcomes can be prediced immediately after completion of the procedure.  

Recent advances in ExAblate technology now enable the treatment of large and vascular fibroids as well as adenomyosis*, broadening the patient base. The ability to treat greater volumes is expected to result in greater clinical efficacy.

Benefits

• Consistent, predictable and immediate results
• Few to no side effects
• Quick recovery time
• No cutting or general anesthesia
• No hospital stay
• No removal of the uterus and cervix.

For women who suffer from symptomatic uterine fibroids, please see our patients' website, http://www.uterine-fibroids.org/

* Not all applications are approved in all regions. Please consult your local representatives and read the product labeling specific for your region to determine approved indications for use.

For more information please contact us